深圳市理邦精密仪器股份有限公司 公司作为中国领先的超声解决方案供应商之一，拥有国际化的营销渠道，并 长期致力于公益医疗，向全球持续输出有价值的医疗创新成果。为了使超声检查 在中低收入国家能广泛开展并可负担，GH Labs 决定根据项目进展分批次向公司 资助共计 2,796,000 美元的项目基金，用以开发一款人工智能驱动的经济型手持 超声设备，供中低收入国家的未经超声专业训练的社区级卫生工作者使用，以识 别产前、围产期妇女的关键高危妊娠风险，估测胎龄等胎儿健康状况，帮助提升 中低收入国家的妇女儿童健康水平。本项目的主要情况如下： 一、 项目相关方情况 名称：Global Health Labs, Inc 地址：14360 SE Eastgate Way, Bellevue, WA 98007 基本情况：成立于 2020 年，是一个创新型的非营利研究机构，专注于通过 创新减少全球，尤其是中低收入国家的卫生差距。GH Labs 作为一家由 Gates Ventures (比尔·盖茨的私人办公室)全额资助的非营利性公司，通过技术创新和 产品开发，推进及实施比尔及梅琳达·盖茨基金会的全球卫生优先事项。 1 证券代码： ...

证券代码：300206 证券简称：理邦仪器 编号：2023-008 深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 □特定对象调研 □分析师会议 投资者关 □媒体采访 ■业绩说明会 系活动类 □新闻发布会 □路演活动 别 □现场参观 □其他 东吴证券、上海证券、太平洋证券、英大资产、上海呈瑞资管、君和资本、金元 顺安、中泰自营、东方自营、名禹资产、中信建投自营、中银基金、信达澳亚、 Barings、鹤禧投资、健顺投资、沣京资管、淡水泉、汇百川基金、阳光资产、 泰聚基金、凯石基金、汇丰晋信、远惟投资、北京知合、英大资产、深圳大道至 参与单位 诚、明世伙伴基金、中再资产、国海资管、申万菱信、禧弘投资、安信基金、金 名称及人 鹰基金、华创资管、首创证券、蜂巢基金、彤源投资、颐和久富、深圳正德泰投 员姓名 资、中意资产、万家基金、上海天猊投资、兴华基金、华安证券、新华基金、复 星恒利、吉渊投资、亚太财险、光大证券、红马投资、西南证券、国联证券、开 源证券、深圳天成时代、国盛证券、景顺长城、工银安盛、上海弢盛资管、泓骐 基金 ...

Revenue and Profit - Revenue for Q3 2023 reached ¥433,641,491.48, an increase of 12.93% year-over-year, while year-to-date revenue totaled ¥1,523,627,959.85, up 22.71% compared to the same period last year[4] - Net profit attributable to shareholders was ¥29,784,719.13, a decrease of 24.22% year-over-year, with year-to-date net profit at ¥236,847,205.87, an increase of 24.83%[4] - Basic earnings per share for Q3 2023 was ¥0.0514, down 23.96% year-over-year, while year-to-date basic earnings per share was ¥0.4086, up 25.18%[4] - Total operating revenue for the current period reached ¥1,523,627,959.85, an increase of 22.7% compared to ¥1,241,682,027.20 in the previous period[22] - Net profit for the current period was ¥239,319,087.90, representing a 27% increase from ¥188,577,923.54 in the previous period[24] - Basic earnings per share increased to ¥0.4086 from ¥0.3264, reflecting a growth of 25.1%[25] - Comprehensive income for the current period totaled ¥241,390,866.54, compared to ¥193,491,080.27 in the previous period, marking a 24.7% increase[25] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥2,217,497,197.10, a decrease of 0.81% from the end of the previous year[4] - As of September 30, 2023, the company's total assets amounted to approximately 2.217 billion RMB, a slight decrease from 2.236 billion RMB at the beginning of the year[19] - The total liabilities decreased from approximately 354 million RMB to about 200 million RMB[19] - Total liabilities decreased to ¥234,810,593.71 from ¥385,028,980.11, indicating a reduction of 38.9%[21] - Total equity attributable to shareholders increased to ¥1,981,950,165.12 from ¥1,853,026,250.52, a growth of 6.9%[21] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥71,447,987.77, down 27.20% compared to the previous year[4] - Cash flow from operating activities generated a net amount of ¥71,447,987.77, down from ¥98,139,816.77 in the previous period[26] - The company's cash and cash equivalents decreased from approximately 957 million RMB at the beginning of the year to about 482 million RMB by September 30, 2023[19] - The total cash and cash equivalents at the end of the period were 472,552,375.30 CNY, down from 524,283,783.18 CNY in the previous period, reflecting a decrease of approximately 9.8%[27] - The company reported a total cash outflow from financing activities of 125,119,868.90 CNY, compared to 190,833,375.63 CNY in the previous period, showing a reduction of about 34.4%[27] - The company experienced a cash flow decrease of 478,070,449.97 CNY in the current period, compared to a decrease of 206,117,057.56 CNY in the previous period, indicating a worsening cash position[27] Investments and Expenses - The company reported a significant increase in construction in progress, which rose by 376.07% to ¥14,574,195.59, attributed to investments in the new industrial building[9] - The company’s financial assets increased by 100% to ¥403,149,589.04, primarily due to new financial investments[9] - Sales expenses increased by 31.89% year-over-year to ¥355,816,383.51, mainly due to higher employee compensation and travel expenses[10] - Investment income decreased by 61.18% year-over-year to ¥1,229,568.30, primarily due to reduced financial investment returns[10] - The company’s cash flow from investing activities showed a net outflow of ¥429,292,956.63, a 239.25% increase in outflow compared to the previous year[12] - Research and development expenses rose to ¥240,281,181.51, an increase of 18.6% compared to ¥202,477,734.44 last year[22] Market Performance - The patient monitoring and in vitro diagnostics segments saw significant growth, increasing by about 37% and 33% year-on-year, respectively[15] - In Q3 2023, the company reported revenue of 434 million RMB, a year-on-year increase of around 13%[15] - Domestic market revenue in Q3 2023 decreased by approximately 5% year-on-year and 18% quarter-on-quarter[15] - International market revenue in Q3 2023 increased by about 30% year-on-year and 9% quarter-on-quarter[15] Accounting and Audit - The company has adopted the new accounting standards starting January 1, 2023, which has led to various adjustments in financial reporting[28] - The company did not undergo an audit for the third quarter report, which may affect the reliability of the financial data presented[30]

证券代码：300206 证券简称：理邦仪器 公告编号：2023-029 深圳市理邦精密仪器股份有限公司 深圳市理邦精密仪器股份有限公司 《2023 年第三季度报告披露提示性公告》、《2023 年第三季度报告》详见 巨潮资讯网，《2023 年第三季度报告披露提示性公告》同时刊载于证券时报、中 国证券报及上海证券报。 表决结果：同意 7 票，反对 0 票，弃权 0 票，获得通过。 特此公告。 第五届董事会 2023年第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2023 年第四次会议于 2023 年 10 月 24 日（星期二）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2023 年 10 月 19 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出席 会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《202 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-030 经审议，监事会认为：董事会编制和审核公司《2023 年第三季度报告》的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2023 年第三季度报告披露提示性公告》、《2023 年第三季度报告》详见 巨潮资讯网，《2023 年第三季度报告披露提示性公告》同时刊载于证券时报、中 国证券报及上海证券报。 表决结果：同意 3 票，反对 0 票，弃权 0 票，获得通过。 特此公告。 深圳市理邦精密仪器股份有限公司 监事会 深圳市理邦精密仪器股份有限公司 第五届监事会 2023年第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届监事会 2023 年第四次会议于 2023 年 10 月 24 日（星期二）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2023 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）于 2021 年 6 月 30 日召开第四届董事会 2021 年第四次会议及第四届监事会 2021 年第四次会议，于 2021 年 7 月 19 日召开的 2021 年第一次临时股东大会审议通过了《关于公司第 二期员工持股计划（草案）及其摘要》的议案，同意公司实施第二期员工持股计 划（以下简称"本员工持股计划"）。 深圳市理邦精密仪器股份有限公司 关于第二期员工持股计划锁定期届满的提示性公告 深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-026 鉴于本员工持股计划锁定期已于 2023 年 9 月 26 日届满，根据中国证监 会《关于上市公司实施员工持股计划试点的指导意见》和深圳证券交易所《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》的相关要 求，现将本员工持股计划锁定期届满后的相关情况公告如下： 一、本员工持股计划的持股情况及锁定期 本员工持股计划的股票来源为公司回购专用证券账户已回购的 ...

证券代码:300206 证券简称:理邦仪器 编号:2023-007 深圳市理邦精密仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------|---------------------------|-------------| | | □特定对象调研 □分析师会议 | | | 投资者关 | □媒体采访 | □业绩说明会 | | 系活动类 | □新闻发布会 ■路演活动 | | | 别 | | | | | □现场参观 | □其他 | 参与单位 德邦证券、西南证券、上海证券、开源证券、东亚前海证券、中山证券、嘉合基 名称及人 金、康曼德资本、中科招商基金、泰康资产管理(香港)、农银汇理、石智基金、 员姓名 上海承周资产、海通资管、华泰宝兴基金、杭州红骅投资等 2023 年 8 月 28 日 10:00 - 11:00、 11:00-12:00 时间 2023 年 8 月 31 日 9:00 - 9:45 、 14:30-15:30 2023 年 9 月 7 日 10:00 - 11:00 地点 深圳福田香格里拉酒店、上海浦东丽晶酒店、上海浦东文华东方酒店、上海浦东 香格里 ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2023, representing a 15% increase compared to the same period in 2022[21]. - The company achieved a revenue of CNY 1,089,986,468.37 in the first half of 2023, representing a growth of 27.08% compared to the same period last year[28]. - Net profit attributable to shareholders reached CNY 207,062,486.74, an increase of 37.65% year-on-year[28]. - The company reported a basic earnings per share of CNY 0.3572, up 38.02% from the previous year[28]. - The company reported a significant increase in user data, with a total of 1.5 million active users, representing a growth of 25% year-over-year[64]. - The revenue for the first half of 2023 reached 500 million RMB, a 15% increase compared to the same period last year[65]. - The company reported a revenue of 1.2 billion RMB for the first half of 2023, representing a year-over-year increase of 15%[67]. - Future guidance indicates a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[65]. - Future outlook includes a revenue growth target of 25% for the full year 2023, driven by market expansion and new product launches[21]. Profitability and Margins - The gross profit margin improved to 45%, up from 42% in the previous year, indicating better cost management and pricing strategies[21]. - The gross margin for the first half of 2023 improved to 45%, up from 42% in the previous year, reflecting better cost management[65]. - The gross profit margin for the patient monitoring segment was 54.04%, up by 2.59% from the previous year[97]. Research and Development - Research and development expenses increased by 30% year-on-year, reflecting the company's commitment to innovation[21]. - The company plans to invest 100 million RMB in R&D over the next two years to accelerate innovation and product development[65]. - The company is actively pursuing innovation in medical devices, as evidenced by the registration of new technologies like the blood oxygen saturation monitor and multi-parameter health monitor[61]. - The company is focusing on innovative solutions for maternal and fetal health, as evidenced by the development of the fetal mother dynamic ECG detection device[55]. - The company has a robust pipeline of new products, with multiple devices registered for use, indicating a strong commitment to research and development in the medical device industry[70][73]. Product Development and Launches - The company plans to launch three new products in the next quarter, focusing on advanced diagnostic technologies[21]. - New product development includes the launch of a digital ECG machine and a dynamic blood pressure recorder, both expected to enhance diagnostic capabilities[67]. - The company is expanding its product line with new devices such as the fetal heart rate monitor and the ambulatory ECG system, which are also in the registration process[56]. - The company has launched a new portable ultrasound diagnostic system, which is expected to enhance clinical examination capabilities and expand market reach[64]. - The company has initiated the registration of several in vitro diagnostic kits, including those for serum amyloid A and C-reactive protein, indicating a strategic move towards expanding its diagnostic portfolio[70][73]. Market Expansion and Strategy - The company is exploring potential acquisitions to enhance its product portfolio and market presence[21]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[67]. - A strategic acquisition of a local competitor is anticipated to be finalized by Q4 2023, which is expected to increase market penetration by 30%[67]. - The company has expanded its distribution network, increasing the number of sales channels by 30% in the last six months[64]. - The company is focusing on innovation and internationalization, with ongoing development of new products and expansion into global markets[36]. Risk Management - Management highlighted risks including quality control and market competition, with strategies in place to mitigate these risks[3]. - The company faces quality control risks due to the technical nature of the medical device industry and has implemented measures to enhance quality management systems[116]. - The company plans to enhance foreign exchange risk management by adjusting the ratio of domestic and foreign sales based on exchange rate changes to mitigate losses[119]. - The company faces significant risks in new product development due to long R&D cycles and high investment, with potential delays in registration affecting project returns[120]. Corporate Governance and Compliance - The company has established specialized committees under the board of directors to ensure effective governance and compliance with legal requirements[137]. - The company has not issued any non-standard audit reports for the half-year financial report, which remains unaudited[146]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, adhering strictly to environmental protection laws[136]. Community Engagement and Social Responsibility - The company has established a volunteer association and launched the "Light Up the Stars" public welfare project to promote community health initiatives, conducting over 70 public welfare activities in the first half of 2023, benefiting more than 5,000 people[140].

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-022 深圳市理邦精密仪器股份有限公司 第五届监事会 2023年第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届监事会 2023 年第三次会议于 2023 年 8 月 22 日（星期二）11:30 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2023 年 8 月 12 日 以电子邮件方式发出。会议应出席监事 3 名，实际出席监事 3 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由监事会主席周纯女士主持， 出席会议的监事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2023 年半年度报告及其摘要》的议案； 监事会经认真审核，认为董事会编制和审核公司 2023 年半年度报告的程序 符合法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了 公司 2023 年半年度经营的实际情况，不存在任何虚假记载、误导性陈述或者 ...

深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2023-021 本议案具体内容详见中国证监会指定信息披露网站同日披露的相关公告。 表决结果：同意 7 票，反对 0 票，弃权 0 票，获得通过。 2、审议通过《关于公司会计政策变更》的议案； 深圳市理邦精密仪器股份有限公司 第五届董事会 2023年第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）第五届董事会 2023 年第三次会议于 2023 年 8 月 22 日（星期二）10:00 在深圳市坪山区坑梓街道金 沙社区金辉路 15 号理邦仪器工业园会议室召开，会议通知于 2023 年 8 月 12 日 以电子邮件方式发出。会议应出席董事 7 名，实际出席董事 7 名。本次会议召开 符合《公司法》及《公司章程》的相关规定。会议由董事长张浩先生主持，出席 会议的董事审议并通过记名投票方式表决通过了如下决议： 1、审议通过《2023 年半年度报告及其摘要》的议案； 1 深圳市理邦精密仪器股份有限公司 深圳市理邦精 ...